An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Randomized controlled trials in oncology can make or break an investigational drug, with both patient lives and pharmaceutical company profits at stake. These trials typically pit two options against ...

Long-term results from the RAISE-XT open-label extension, presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting, demonstrated sustained improvements in ...

When REDCap did not offer a way to use covariate-adaptive randomization algorithms (CARAs), researchers realized they would ...

Background: Primary care physicians, who manage the care of most children with asthma, often do not optimally assess disease control, prescribe asthma controller medications, or provide family asthma ...

Augmenting the management of obstructive sleep apnea (OSA) with consumer wearable devices increases the use of positive airway pressure (PAP) therapy, according to the results of a pilot randomized tr ...

Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer A key but often overlooked question in oncology clinical ...

NOVEMBER IS RECOGNIZED AS NATIONAL ALZHEIMER’S AWARENESS MONTH, A FIRST OF ITS KIND CLINICAL TRIAL IS CHANGING THE LIVES OF ...

The UK has launched two major trials as part of a longer research program to rigorously investigate the impact of puberty ...

Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...